Wolters Kluwer Health acquires Firecracker

Cara Livernois | | Health Exec | Economics

Wolters Kluwer Health acquired Firecracker, an adaptive learning and study-planning application used by 20 percent of medical students, following a March 5 announcement of a signed agreement.

Firecracker will become part of Wolters Health Learning, Research & Practice group to provide medical education and practice content. The Firecracker platform provides students with answers to more than 85 million questions a year.

“We’re excited to expand our portfolio of online evidence-based learning tools with Firecracker’s proven technology,” said Diana Nole, CEO, Wolters Kluwer Health. “Combined with Lippincott premium content and solutions, Firecracker enhances our position in the medical education market and helps us further leverage machine learning and advanced technologies to help clinicians deliver the best quality care to patients.”

The adaptive algorithm aims to help students in remediation in ongoing retention and preparedness for final exams and certifications. It has improved student performance in the U.S. Medical License Exams by an average of 13 points.

""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Related Content

Eli Lilly to acquire gene-editing specialists focused on CVD for up to $1.3B
Why more doctors should pursue business and leadership training
Q&A: The role of employers in achieving healthcare price transparency
Medtronic’s diabetes spin-off gets a name, kicking off ‘new and exciting chapter’
Smaller revenues, less growth: In US, tariffs may create headaches for $34.5B cardiovascular device market
How private equity influences care for heart failure patients

Around the web

Cardiovascular Business
Eli Lilly to acquire gene-editing specialists focused on CVD for up to $1.3B

The company has agreed to acquire Verve Therapeutics for an upfront payment of approximately $1 billion. The total could increase significantly, however, if certain milestones are met. One of Verve's biggest gene therapies has already received the FDA's fast track designation.

Cardiovascular Business
AMA House of Delegates helps cardiology groups influence healthcare policies

American College of Cardiology Board of Governors Chair David E. Winchester, MD, MS, examines the many benefits of working with the American Medical Association House of Delegates to bring about significant change.

Cardiovascular Business
Smaller revenues, less growth: In US, tariffs may create headaches for $34.5B cardiovascular device market

“Without a more concrete and stable policy on these tariffs from the current American administration, it is likely that most manufacturers will be forced to continuously change their internal forecasts and production plans," one analyst said.